Ljubljana, Slovenia

Jelka Svetek

This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Lek Pharmaceuticals D.d.. Active years: 2009-2014.




Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2009-2014

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jelka Svetek: Innovator in Pharmaceutical Composition

Introduction

Jelka Svetek is a prominent inventor based in Ljubljana, Slovenia. She has made significant contributions to the field of pharmaceuticals, particularly in the stabilization of erythropoietin (EPO) compositions. With a total of 2 patents, her work has the potential to impact the medical industry positively.

Latest Patents

Jelka's latest patents include a stable pharmaceutical composition comprising erythropoietin that is stabilized with PVP. This innovative formulation aims to enhance the stability and efficacy of EPO. Additionally, she has developed another stable pharmaceutical composition of erythropoietin that utilizes a combination of a poloxamer polyol and a polyhydric alcohol for stabilization.

Career Highlights

Jelka Svetek is currently employed at Lek Pharmaceuticals D.d., a leading pharmaceutical company in Slovenia. Her work at Lek has allowed her to focus on developing advanced pharmaceutical formulations that address critical medical needs.

Collaborations

Jelka has collaborated with notable colleagues, including Tanja Rozman Peterka and Alenka Paris. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Jelka Svetek's contributions to pharmaceutical innovation, particularly in the stabilization of erythropoietin, highlight her role as a key inventor in the industry. Her work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…